Toll-Like Receptor Agonists in Cancer Immunotherapy

Toll-like receptors (TLRs) are evolutionarily conserved pattern-recognition molecules that bridge innate and adaptive immune responses by sensing microbial and endogenous danger signals. Agonists targeting various TLR subtypes have been harnessed to activate antigen-presenting cells, promote cytokine secretion, and drive cytotoxic T-lymphocyte and natural killer-cell recruitment within the tumour microenvironment. By converting immunologically “cold” tumours into “hot” lesions, TLR agonists can potentiate the efficacy of immune checkpoint inhibitors and conventional therapies. Formulations range from small-molecule ligands, such as imiquimod (TLR7) and CpG oligonucleotides (TLR9), to synthetic RNA duplexes for TLR3 and lipophilic constructs for TLR7/8, with administration routes tailored to maximise local activity and minimise systemic inflammation. Emerging strategies employ biomimetic nanoparticles, autologous cell-based vaccines and combination regimens with epigenetic or co-stimulatory agents to enhance specificity, durability and safety. Collectively, these approaches underscore the global significance of TLR agonists as versatile adjuvants and stand-alone immunotherapies in cancer treatment.

Research from Nature Portfolio

Researchers have developed a chemically defined double-stranded RNA ligand that selectively engages TLR3 without triggering RIG-I/MDA5 pathways. This sODN-dsRNA construct elicits minimal systemic cytokinaemia yet robustly activates the TLR3–TICAM-1 axis in dendritic cells, leading to potent natural killer and cytotoxic T-cell responses in tumour-bearing models. The study demonstrates durable antitumour immunity following local administration, highlighting the feasibility of precise TLR3 engagement for safe and effective cancer immunotherapy.

Toll-Like Receptor Agonists in Cancer Immunotherapy publication trend

The graph below shows the total number of articles in toll-like receptor agonists in cancer immunotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

Toll-like receptor (TLR): A membrane-bound pattern-recognition receptor that detects microbial or danger-associated molecular patterns to initiate innate immunity.

Agonist: A molecule that binds to and activates a receptor, mimicking the effect of a natural ligand.

Dendritic cell (DC): A professional antigen-presenting cell that processes and presents antigens to T cells, bridging innate and adaptive responses.

Tumour microenvironment (TME): The complex milieu of cancer cells, stromal elements, immune infiltrates and signalling molecules surrounding a tumour.

Adjuvant: A substance that enhances the magnitude or quality of the immune response to an antigen, often by stimulating innate pathways.

References

1. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune. Journal of Nanobiotechnology (2024).
2. rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses. Journal of Experimental & Clinical Cancer Research (2023).
3. Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer. npj Precision Oncology (2023).
4. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy. Frontiers in Immunology (2023).
5. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. Journal for ImmunoTherapy of Cancer (2019).
6. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. Nature Communications (2015).